RT Journal Article
T1 Development of a Lateral Flow Assay for the Detection of the Hepatitis C Virus Core Antigen
A1 Vidal-Alcántara, Erick Joan
A1 Hernández Antón, Sonia
A1 Rueda, Paloma
A1 Yélamos López, María Belén
A1 Gómez Gutiérrez, Julián
A1 Resino, Salvador
A1 Fresco-Taboada, Alba
A1 Martínez, Isidoro
AB Background: Hepatitis C virus (HCV) infection remains a global health challenge, with millions of people affected annually. Current diagnostic methods, reliant on antibody screening and viral RNA detection, are complex, costly, and often inaccessible, particularly in resource-limited settings. Aim: Development of a lateral flow immunochromatography-based assay for detecting the highly conserved hepatitis C core antigen (HCVcAg). Methods: The assay relies on the interaction of four highly specific and cross-reactive monoclonal antibodies with recombinant HCVcAg from five different genotypes in a double antibody sandwich format. Latex and colloidal gold were evaluated as detector nanoparticles. Results: Extensive evaluation of 32 antibody combinations led to identifying the most sensitive antibody pairs. The chosen assay, named LN17, demonstrated a target sensitivity of 10 ng/strip, with potential clinical implications for detecting HCV. Furthermore, the study examined matrix effects in serum samples, providing valuable insights for future clinical application. Conclusions: The developed assay holds promise as a rapid, cost-effective, and user-friendly tool to enhance accessibility to hepatitis C screening, especially in high-risk populations and resource-limited environments.
PB MDPI
SN 1424-8247
YR 2024
FD 2024-08-04
LK https://hdl.handle.net/20.500.14352/134530
UL https://hdl.handle.net/20.500.14352/134530
LA eng
NO Vidal-Alcántara, E. J., Antón, S. H., Rueda, P., Yélamos, M. B., Gómez, J., Resino, S., Fresco-Taboada, A., & Martínez, I. (2024). Development of a Lateral Flow Assay for the Detection of the Hepatitis C Virus Core Antigen. Pharmaceuticals, 17(8), 1022. https://doi.org/10.3390/ph17081022
NO Instituto de Salud Carlos III
NO Centro de Investigación Biomédica en Red de Enfermedades infecciosas (CIBERINFEC)
DS Docta Complutense
RD 27 abr 2026